8-K: Teva Shareholders Affirm Board, Executive Compensation, and Auditor Appointments at Annual Meeting

Teva Pharmaceutical Industries Ltd. announced that its shareholders approved all proposals at the Annual Meeting on June 5, 2025, including the election of directors and various compensation-related amendments.

Summary

• Shareholders of Teva Pharmaceutical Industries Limited held their Annual Meeting on June 5, 2025.
• Five directors were elected to the Board: Chen Lichtenstein (until 2027 annual meeting), and Amir Elstein, Roberto A. Mignone, Dr. Perry D. Nisen, and Dr. Tal Zaks (all until 2028 annual meeting).
• The non-binding advisory proposal for the compensation of Teva's named executive officers was approved with 688,836,027 votes For.
• An amended Compensation Policy for Executive Officers and Directors was approved with a total of 710,166,047 votes For.
• An amendment to the terms of office and employment for Teva's President and Chief Executive Officer was approved with 723,482,261 votes For.
• Amendments to the compensation for non-employee Directors and the non-executive Chairman of the Board were approved with 773,824,912 and 772,020,910 votes For, respectively.
• Kesselman & Kesselman, a member of PricewaterhouseCoopers International Ltd., was approved as Teva's independent registered public accounting firm until the 2026 annual meeting, with 820,210,234 votes For.

Sentiment

Score: 7

Explanation: The successful passage of all management-backed proposals, including director elections and compensation policies, indicates strong shareholder support and corporate stability, reflecting a generally positive sentiment regarding governance.

Positives

• All proposals presented at the Annual Meeting were approved by shareholders, indicating strong support for the company's current governance and compensation structures.
• The election of directors ensures continuity and stability in the company's leadership.
• The approval of the independent registered public accounting firm provides assurance of continued financial oversight and compliance.

Negatives

• While all proposals passed, there were significant 'Against' votes and 'Brokers non-vote' for several items, indicating some level of dissent or uninstructed shares.

Future Outlook

The document primarily reports on past voting results and does not provide forward-looking statements regarding financial performance or strategic business initiatives, beyond the terms of elected directors and appointed auditors extending to future annual meetings.

Industry Context

This filing pertains specifically to Teva's internal corporate governance matters and does not contain information related to broader pharmaceutical industry trends, competitive landscape, or market conditions.

Corporate Governance

Related Party Transactions

• The vote on the amended Compensation Policy included a specific breakdown for shareholders 'Indicating YES for personal interest', highlighting that individuals with a direct stake in the compensation terms participated in the vote, as is typical for such proposals.

Stakeholder Impact

• Shareholders: Exercised their voting rights on key governance matters, including director elections and compensation policies.
• Directors and Executive Officers: Their terms of office and compensation structures were affirmed or amended based on shareholder votes.
• Auditors: Kesselman & Kesselman (PwC) was re-appointed, ensuring continuity in external financial auditing.

Next Steps

• Elected directors will serve their respective terms until the 2027 or 2028 annual meetings.
• The appointed independent registered public accounting firm will serve until the 2026 annual meeting.
• The approved compensation policies and terms for executives and directors will be implemented.

Key Dates

Recommendation

Keywords

Teva Pharmaceutical Industries, Shareholder Meeting, Annual Meeting, Corporate Governance, Director Election, Executive Compensation, Compensation Policy, Auditor Appointment, SEC Filing, 8-K